vs

Side-by-side financial comparison of Arcturus Therapeutics Holdings Inc. (ARCT) and IF Bancorp, Inc. (IROQ). Click either name above to swap in a different company.

IF Bancorp, Inc. is the larger business by last-quarter revenue ($7.3M vs $7.2M, roughly 1.0× Arcturus Therapeutics Holdings Inc.). On growth, IF Bancorp, Inc. posted the faster year-over-year revenue change (16.8% vs -68.4%). IF Bancorp, Inc. produced more free cash flow last quarter ($1.7M vs $-74.5M). Over the past eight quarters, IF Bancorp, Inc.'s revenue compounded faster (16.5% CAGR vs -56.5%).

Arcturus Therapeutics Holdings Inc. is an American RNA medicines biotechnology company focused on the discovery, development and commercialization of therapeutics for rare diseases and infectious diseases. Arcturus has developed proprietary lipid nanoparticle RNA therapeutics for nucleic acid medicines including small interfering RNA (siRNA), messenger RNA (mRNA), gene editing RNA, DNA, antisense oligonucleotides, and microRNA.

U.S. Bancorp is an American multinational banking institution headquartered in Minneapolis, Minnesota and incorporated in Delaware. It is the 5th-largest bank in the United States as of 2025. As the largest bank in the Midwestern United States, it is considered systemically important by the Financial Stability Board. It is the parent company of its primary operating entity, U.S. Bank National Association, which does business as U.S. Bank. The company provides banking, investment, mortgage, tr...

ARCT vs IROQ — Head-to-Head

Bigger by revenue
IROQ
IROQ
1.0× larger
IROQ
$7.3M
$7.2M
ARCT
Growing faster (revenue YoY)
IROQ
IROQ
+85.2% gap
IROQ
16.8%
-68.4%
ARCT
More free cash flow
IROQ
IROQ
$76.2M more FCF
IROQ
$1.7M
$-74.5M
ARCT
Faster 2-yr revenue CAGR
IROQ
IROQ
Annualised
IROQ
16.5%
-56.5%
ARCT

Income Statement — Q4 FY2025 vs Q2 FY2026

Metric
ARCT
ARCT
IROQ
IROQ
Revenue
$7.2M
$7.3M
Net Profit
$1.3M
Gross Margin
Operating Margin
24.9%
Net Margin
18.1%
Revenue YoY
-68.4%
16.8%
Net Profit YoY
3.1%
8.9%
EPS (diluted)
$0.41

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ARCT
ARCT
IROQ
IROQ
Q4 25
$7.2M
$7.3M
Q3 25
$17.2M
$7.3M
Q2 25
$28.3M
$6.9M
Q1 25
$29.4M
$6.4M
Q4 24
$22.8M
$6.3M
Q3 24
$41.7M
$6.2M
Q2 24
$49.9M
$5.7M
Q1 24
$38.0M
$5.4M
Net Profit
ARCT
ARCT
IROQ
IROQ
Q4 25
$1.3M
Q3 25
$-13.4M
$1.4M
Q2 25
$-9.2M
$1.4M
Q1 25
$-14.1M
$1.0M
Q4 24
$-30.0M
$1.2M
Q3 24
$-6.9M
$633.0K
Q2 24
$-17.2M
$431.0K
Q1 24
$-26.8M
$708.0K
Operating Margin
ARCT
ARCT
IROQ
IROQ
Q4 25
24.9%
Q3 25
-96.3%
26.0%
Q2 25
-41.0%
29.1%
Q1 25
-57.3%
21.7%
Q4 24
-146.7%
26.8%
Q3 24
-25.8%
13.7%
Q2 24
-42.4%
9.3%
Q1 24
-80.0%
17.6%
Net Margin
ARCT
ARCT
IROQ
IROQ
Q4 25
18.1%
Q3 25
-78.4%
19.0%
Q2 25
-32.4%
21.0%
Q1 25
-47.9%
15.8%
Q4 24
-131.8%
19.4%
Q3 24
-16.6%
10.2%
Q2 24
-34.5%
7.6%
Q1 24
-70.5%
13.1%
EPS (diluted)
ARCT
ARCT
IROQ
IROQ
Q4 25
$0.41
Q3 25
$-0.49
$0.43
Q2 25
$-0.34
$0.48
Q1 25
$-0.52
$0.31
Q4 24
$-1.10
$0.38
Q3 24
$-0.26
$0.20
Q2 24
$-0.64
$0.15
Q1 24
$-1.00
$0.22

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ARCT
ARCT
IROQ
IROQ
Cash + ST InvestmentsLiquidity on hand
$230.9M
$8.8M
Total DebtLower is stronger
Stockholders' EquityBook value
$214.0M
$87.4M
Total Assets
$271.1M
$830.4M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ARCT
ARCT
IROQ
IROQ
Q4 25
$230.9M
$8.8M
Q3 25
$180.4M
$8.0M
Q2 25
$196.5M
$20.1M
Q1 25
$216.9M
$8.9M
Q4 24
$237.0M
$5.9M
Q3 24
$237.2M
$7.8M
Q2 24
$260.3M
$9.6M
Q1 24
$288.4M
$16.1M
Stockholders' Equity
ARCT
ARCT
IROQ
IROQ
Q4 25
$214.0M
$87.4M
Q3 25
$224.6M
$84.5M
Q2 25
$231.1M
$81.8M
Q1 25
$233.8M
$78.9M
Q4 24
$241.0M
$75.9M
Q3 24
$261.9M
$78.8M
Q2 24
$258.6M
$73.9M
Q1 24
$264.0M
$72.4M
Total Assets
ARCT
ARCT
IROQ
IROQ
Q4 25
$271.1M
$830.4M
Q3 25
$282.3M
$862.3M
Q2 25
$309.3M
$887.7M
Q1 25
$331.8M
$879.1M
Q4 24
$344.1M
$885.1M
Q3 24
$370.7M
$893.4M
Q2 24
$388.6M
$887.7M
Q1 24
$418.8M
$905.0M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ARCT
ARCT
IROQ
IROQ
Operating Cash FlowLast quarter
$-74.3M
$1.8M
Free Cash FlowOCF − Capex
$-74.5M
$1.7M
FCF MarginFCF / Revenue
-1035.2%
23.7%
Capex IntensityCapex / Revenue
3.2%
0.9%
Cash ConversionOCF / Net Profit
1.36×
TTM Free Cash FlowTrailing 4 quarters
$9.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ARCT
ARCT
IROQ
IROQ
Q4 25
$-74.3M
$1.8M
Q3 25
$-17.2M
$-539.0K
Q2 25
$-5.8M
$6.8M
Q1 25
$-35.1M
$1.8M
Q4 24
$-284.0K
$-155.0K
Q3 24
$-23.8M
$2.2M
Q2 24
$-30.1M
$2.3M
Q1 24
$-5.6M
$19.0K
Free Cash Flow
ARCT
ARCT
IROQ
IROQ
Q4 25
$-74.5M
$1.7M
Q3 25
$-17.3M
$-582.0K
Q2 25
$6.5M
Q1 25
$-35.3M
$1.8M
Q4 24
$-226.0K
Q3 24
$-23.8M
$2.1M
Q2 24
$-30.5M
$2.0M
Q1 24
$-5.8M
$-67.0K
FCF Margin
ARCT
ARCT
IROQ
IROQ
Q4 25
-1035.2%
23.7%
Q3 25
-101.1%
-7.9%
Q2 25
95.1%
Q1 25
-120.1%
28.2%
Q4 24
-3.6%
Q3 24
-57.2%
33.6%
Q2 24
-61.1%
35.7%
Q1 24
-15.3%
-1.2%
Capex Intensity
ARCT
ARCT
IROQ
IROQ
Q4 25
3.2%
0.9%
Q3 25
1.1%
0.6%
Q2 25
0.0%
3.5%
Q1 25
0.5%
0.4%
Q4 24
0.0%
1.1%
Q3 24
0.2%
1.2%
Q2 24
0.7%
4.3%
Q1 24
0.6%
1.6%
Cash Conversion
ARCT
ARCT
IROQ
IROQ
Q4 25
1.36×
Q3 25
-0.39×
Q2 25
4.69×
Q1 25
1.81×
Q4 24
-0.13×
Q3 24
3.42×
Q2 24
5.30×
Q1 24
0.03×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons